Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

ST. LOUIS, Dec. 12, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or "the Company") today announced that it has received a commitment from lenders led by an affiliate of Silver Point Finance LLC for $85 million in senior secured post-petition debtor-in-possession ("DIP") financing, which the Company intends to use to, among other things, satisfy the terms of its recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"), provide additional financial flexibility during the pendency of the Company's Chapter 11 proceeding and fund certain payments under a proposed reorganization plan.  The new DIP financing, the Hologic Settlement and the reorganization plan (and related disclosure statement)  are each subject to approval of the U. S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding.

The Hologic Settlement confirms K-V's continued ownership of Makena® and will resolve all bankruptcy related disputes between K-V and Hologic, and provides for mutual releases of all claims between the parties. 

Under the proposed reorganization plan, K-V expects to emerge from Chapter 11 with its entire product portfolio, including Makena®, Clindesse®, Gynazole-1® and Evamist®.  The Company has provided and is committed to continue to provide its women's health care products without interruption to meet the needs of the health care providers and patients it serves.

Prior to the funding of the DIP financing facility, K-V intends to file with the Bankruptcy Court a proposed reorganization plan, a related disclosure statement, and a plan support agreement (PSA) with an ad hoc group of senior secured noteholders.  The principal terms of the proposed reorganization plan are contained in a plan term sheet filed with the motion to approve the DIP financing filed with the Bankruptcy Court, which together with other documents from the Chapter
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Calif., Dec. 12 Codexis, Inc., a leading,developer ... directors have been named to the company,s Board ... Vice President of Innovation and,Chemicals Technology, Shell Global ... Dennis Wolf, Executive Vice President and CFO, MySQL, ...
... PLYMOUTH MEETING, Pa., Dec. 12 Genaera,Corporation (Nasdaq: ... Executive Officer of Genaera, is scheduled to present at ... part of an,RBC Capital Markets, panel discussion of diabetes ... and will take place in,New York on Thursday, December ...
... First Time on 50 mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive ... of Wyeth (NYSE: WYE ), announces that data from,two ... inhibitor (SNRI), showed,that adult patients who received a 50 mg/day ...
Cached Biology Technology:Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... Change , suggests that if current trends continue ... targets for total greenhouse gas (GHG) emissions in 2050. ... about the food we choose and its environmental impact. A ... of a number of actions that need to be taken ... food for all. , As populations rise and global ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... into a calcium-sensing enzyme already known to play a ... researchers showed that the enzyme, calmodulin kinase II (CaM ... disease called Timothy syndrome and that inhibiting the enzyme ... a new cellular model, could help with developing treatments ...
... Climate change can have significant impacts on high-elevation lakes ... them, according to U.S. Forest Service and University of ... issue of the journal " Herpetological Conservation and Biology ... shallow lakes drying up in summer and predation by ...
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
Cached Biology News:Rare disease provides clues about enzyme role in arrhythmias 2Rare disease provides clues about enzyme role in arrhythmias 3Climate change effects on imperiled Sierra frog examined 2UQ research targets West Nile virus and dengue fever 2
NORMAL DONOR DONKEY SERUM...
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Biology Products: